Table IV.

Adverse events of interest.

	ESA-naïve	Prior ESA-treated
	n = 144	n = 62
Patients who had adverse events of interest, n (%)	34 (24)	21 (34)
Neoplasms benign, malignant and unspecified, n (%)	12 (8)	9 (15)
Hypertension, n (%)	7 (5)	4 (6)
Cardiovascular and thromboembolic events	18 (12)	10 (16)
Arrhythmias, n (%)	5 (3)	2 (3)
Cerebrovascular accident, n (%)*	6 (4)	1 (2)
Congestive heart failure, n (%)	4 (3)	2 (3)
Myocardial infarction/coronary artery disorders, n (%)	3 (2)	3 (5)
Embolism/thrombosis, n (%)	1 (1)	3 (5)
Immune system disorders, n (%)	1 (1)	0 (0)
Seizure, n (%)	1 (1)	0 (0)
Pure red cell aplasia	0 (0)	0 (0)

ESA, erythropoiesis-stimulating agent.

*Includes five thrombotic events, one haemorrhagic event and one event of unknown aetiology.